Upload
esben
View
18
Download
0
Embed Size (px)
DESCRIPTION
CONNECTICUT PUBLIC HEALTH ASSOCIATION HEALTH EDUCATION COMMITTEE 6-12-2013. DEBBYE ROSEN, BSN, MS ADULT IMMUNIZATION COORDINATOR CT DEPARTMENT OF PUBLIC HEALTH 860-509-7729 [email protected]. REVIEW INFLUENZA SURVEILLANCE FOR 2012-2013, CT AND NATIONAL - PowerPoint PPT Presentation
Citation preview
CONNECTICUT PUBLIC HEALTH ASSOCIATIONHEALTH EDUCATION COMMITTEE
6-12-2013
DEBBYE ROSEN, BSN, MSADULT IMMUNIZATION
COORDINATORCT DEPARTMENT OF PUBLIC HEALTH
• REVIEW INFLUENZA SURVEILLANCE FOR 2012-2013, CT AND NATIONAL
• REVIEW INFLUENZA VACCINATION DATA, NATIONAL 2012-2013
• INFLUENZA VACCINE RECOMMENDATIONS 2013-2014
• INFLUENZA VACCINE PRODUCTS 2013-2014
• UPDATE H7N9 – IS THIS THE “NEW” PANDEMIC
OBJECTIVES
• DESCRIBE THE INFLUENZA SURVEILLANCE PROCESS
• LIST THE 2012-2013 INFLUENZA VACCINATION RECOMMENDATIONS
• LIST THE KEY POINTS TO FOLLOW IN THE H7N9 INFLUENZA
OUTBREAK
BURDEN OF DISEASE, U.S. ADULTS
INFLUENZA• 3,000 to 49,000 total related deaths per year • ~90% among adults 65 years and older
Invasive pneumococcal disease (IPD)1 • 39,750 total cases and 4,000 total deaths in 2010
• 86% of IPD and nearly all IPD deaths among adults
Pertussis• 41,880 total reported cases 2012 • ~9,000 among adults
Hepatitis B • 3,350 acute cases reported 2010 • 35,000 estimated
Zoster • about 1 million cases of zoster annually in the U.S.
1.CDC. Active Bacterial Core Surveillance. http://www.cdc.gov/abcs/reports-findings/survreports/spneu10.pdf. 2.CDC. Estimates of deaths associated with seasonal influenza – United States, 1976-2007. MMWR. 2010;59(33):1057-1062.
3.CDC. Notifiable Diseases and Mortality Tables. MMWR 2013. 61(51&52): ND-719 – ND 732. 4.CDC. Viral Hepatitis Surveillance United States, 2010. National Center for HIV/AIDS, Viral Hepatitis, STD& TB Prevention/Division of Viral Hepatitis.
5.CDC. Prevention of Herpes Zoster. MMWR 2008. 57(RR-5): 1-30.
WHERE DO THE NUMBERS COME FROM?????
INFLUENZA SURVEILLANCE
NATIONAL DATA•CULTURE CONFIRMED FROM STATES •INFLUENZA LIKE ILLNESS•DEATHS FROM PNEUMONIA AND INFLUENZA-CITIES
• DEATHS IN CHILDREN <5 YRS•CULTURE POSITIVE HOSPITALIZED PATIENTS
CONNECTICUT•EMERGENCY ROOM VISITS
DEATHS , INFLUENZA RELATED CT 2012-2013
• TOTAL= 37• 89% >65 YRS, 11% 55-64 YRS
• NO DEATHS < 5 YRS.
• MODERATE TO SEVERE SEASON• EARLY DISEASE• ELDERLY SEVERELY IMPACTED
MEASURING INFLUENZA VACCINATIONS
VACCINATION RATES• BRFSS (ADULTS)
• NATIONAL IMMUNIZATION SURVEY (CHILDREN)
• NHIS (ADULTS)
• NATIONAL FLU SURVEY (ADULTS,HCP, PREGNANT)
VACCINE EFFECTIVENESS
VACCINE EFFECTIVENESS
• INFLUENZA A & B VIRUS ASSOCIATED WITH MEDICALLY ATTENDED ACUTE RESPIRATORY ILLNESS 56%
47% AGAINST INFLUENZA A (H3N2)67 % AGAINST INFLEUNZA B
23% (9%) AGAINST INFLUENZA A (H3N2) PEOPLE > 65 YRS
WHO SHOULD GET VACCINATED IN 2013-2014
•> 6 MONTHS
WHO SHOULD NOT GET VACCINATED•SEVERE REACTION TO PREVIOUS FLU VACCINE•GUILLAIN-BARRÉ•< 6 MONTHS•MODERATE SEVERE ILLNESS•EGG ALLERGY ????????
FLU VACCINE PRODUCTS 2013-2014
• 10 VACCINE PRODUCTS
• 6 MANUFACTURERS
• NEW PRODUCTS• LIV4
• IIV4
• CELL CULTURE (ccIIV3)• RECOMBINANT HEMAGGLUTIN
INFLUENZA VACCINE (RIV3 FLUBLOK)
H7N9 ????????THE NEXT PANDEMIC
• > 130 CASES IDENTIFIED IN 10 CHINA PROVINCES
• NO U.S. CASES
• NO SUSTAINED HUMAN TO HUMAN TRANSMISSION
• TESTING KITS ARE AVAILABLE
• CANDIDATE VACCINE DEVELOPED• CLINICAL TRIALS• # OF DOSES NEEDED• ADJUVANT TO BOOST RESPONSE
RESOURCES
• CENTERS FOR DISEASE CONTROL AND PREVENTION www.cdc.gov/flu
• DEPARTMENT OF PUBLIC HEALTH IMMUNIZATION PROGRAM
www.ct.gov/dph/immunizations
• IMMUNIZATION ACTION COALITIION www.immunize.org
DEBBYE ROSEN, BSN, MSADULT IMMUNIZATION
COORDINATORCT DEPARTMENT OF PUBLIC HEALTH
????????????????????????????